Communiqués ValiRx plc

Actions

Marché Fermé - London S.E. Autres places de cotation 17:35:19 07/06/2024			Varia. 5j.	Varia. 1 janv.
2,85 ^GBX	+3,64 %		-3,39 %	-51,69 %

20/05	Londres stimulée par l'espoir d'une baisse des taux d'intérêt	AN
20/05	Les actions de ValiRx bondissent suite à l'obtention par Cytolytix d'une subvention au titre du transfert de connaissances	AN

ValiRx strikes deal with Ambrose Healthcare to license late-stage cancer treatment	06/12	AQ
ValiRx signals launch of new strategy with Nottingham laboratories	01/02/23	AQ
ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment	16/12/22	AQ
ValiRx signs IP license agreement with Kings College London to progress triple negative breast cancer treatment	25/10/22	AQ
ValiRx appoints NED to support growth and investment drive	20/10/22	AQ
ValiRx Plc - Ada Lovelace Day 2022, in conversation with ValiRx's CEO	12/10/22	AQ
ValiRx : Exercise of Warrant	30/09/20	AQ
ValiRx : Share Price Movement, Exercise of Warrant	24/09/20	AQ
ValiRx : Exercise of Warrants and Warrant Update	15/09/20	AQ
VALIRX : HALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2020	08/09/20	AQ
ValiRx : Exercise of Warrant	08/09/20	AQ
ValiRx : Exercise of Warrants	31/08/20	AQ
ValiRx : Block Listing Application and Company Update	20/08/20	AQ
ValiRx : Director Dealing	10/08/20	AQ
ValiRx : Broker Option, Fully Subscribed	27/07/20	AQ
ValiRx : Result of AGM	24/07/20	AQ
ValiRx : Oversubscribed Placing and Fundraise	24/07/20	AQ
ValiRx : Pre-AGM Statement	24/07/20	AQ
ValiRx : Notice of AGM	02/07/20	AQ
ValiRx : Share Price Movement	04/05/20	AQ

Aucun résultat pour cette recherche